Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | FHL2 |
| Gene Name: | FHL2 |
| Protein Full Name: | Four and a half LIM domains protein 2 |
| Alias: | DRAL; DRAL, SLIM3; FHL-2; Four and a half LIM domains 2; LIM-domain protein DRAL; Skeletal muscle LIM- protein 3; SLIM 3; SLIM3 |
| Mass (Da): | 32193 |
| Number AA: | 279 |
| UniProt ID: | Q14192 |
| Locus ID: | 2274 |
| COSMIC ID: | FHL2 |
| Gene location on chromosome: | 2q12.2 |
| Cancer protein type: | BOTH |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.18 |
| Normal role description: | FHL2 is involved in osteoblasts and myoblast differentiation, adhesion, motility, cell proliferation, transcription and signal transduction. It is a co-activator for androgen receptor, BRCA1, AP-1, CREB, WT-1 and more. It has also been found to supprest ERK2, SRF and FOXO1. |